AII
AGIO icon

AGF Investments Inc’s Agios Pharmaceuticals AGIO Stock Holding History

AGF Investments Inc’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,200
Closed -$194K – 719
2021
Q3 		$194K Buy
+4,200
New +$203K ﹤0.01% 545

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AGF Investments Inc's AGIO Position: Q4 2021 in Review

AGF Investments Inc sold out of Agios Pharmaceuticals (AGIO) in Q4 2021, closing a stake of 4,200 shares — an estimated $194K sold.

AGF Investments Inc first reported a position in AGIO in Q3 2021 and held it in 1 quarter. The position peaked at $194K in Q3 2021. 160 funds tracked by Wall St. Rank hold AGIO as of Q4 2021.

  • AGF Investments Inc reported no remaining Agios Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • AGF Investments Inc sold 4,200 Agios Pharmaceuticals shares in Q4 2021, an estimated $194K.
  • AGF Investments Inc first reported a position in Agios Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • AGF Investments Inc's Agios Pharmaceuticals position peaked at $194K in Q3 2021.
  • 160 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2021.

Based on AGF Investments Inc's 13F filing for Q4 2021, filed 1 Feb 2022.